Trial NCT04444674
Publication Koen A, medRxiv, 2022
Primary outcome on the report: VE in the context of polymerase chain reaction (PCR)-positive symptomatic COVID-19 occurring >14 days after the second dose of study drug, and safety

Note: The risk of bias by domain corresponds to the highest risk of bias among outcomes by domain.
The overall risk of bias corresponds to the overall highest risk of bias assessed among outcomes.